StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
18
This year
3
Publishing Date
2024 - 03 - 25
1
2024 - 03 - 08
1
2024 - 03 - 05
1
2023 - 10 - 09
1
2023 - 09 - 26
1
2023 - 06 - 28
1
2023 - 04 - 19
1
2022 - 09 - 01
1
2022 - 07 - 25
1
2022 - 06 - 27
1
2022 - 05 - 11
1
2021 - 11 - 12
1
2021 - 08 - 06
1
2021 - 07 - 29
1
2021 - 07 - 21
1
2021 - 07 - 09
2
2021 - 06 - 22
1
Sector
Finance
1
Health services
1
Health technology
18
Tags
Acquire
7
Agreement
5
Application
6
Approval
7
Biotech
7
Biotechnology
5
Bleeding
7
Blood
5
Cancer
5
Cardiovascular
5
Collaboration
8
Companies
6
Conference
20
Device
5
Diabetes
34
Disease
18
Drug
18
Earnings
8
Europe
10
Events
22
Expansion
7
Expected
10
Fda
11
Financial
7
Financial results
7
Genetown
7
Global
45
Growing
5
Growth
33
Hormone
7
Insulin
32
Iot
6
Kidney
5
Liver
11
Market
78
Money
7
N/a
516
Obesity
16
People
11
Pharma
81
Pharmaceutical
12
Phase 2
7
Phase 3
6
Program
10
Reach
9
Report
38
Repurchase
96
Research
34
Results
20
S
42
Sales
13
Sanofi
7
Study
6
Technology
10
Therapeutics
26
Therapy
11
Treatment
34
Trial
32
Trials
8
Update
12
Entities
4d molecular therapeutics inc
14
Abbott laboratories
67
Abbvie inc.
65
Ac immune sa
21
Acumen pharmaceuticals inc
14
Aldeyra therapeutics, inc.
17
Alnylam pharmaceuticals, inc.
13
Alterity therapeutics limited
14
Amgen inc.
26
Amicus therapeutics, inc.
20
Anavex life sciences corp.
24
Annovis bio, inc.
29
Astellas pharma inc
16
Astrazeneca plc
34
Athira pharma, inc.
24
Bausch health companies inc.
20
Beam therapeutics inc.
15
Becton, dickinson and company
24
Bio-rad laboratories, inc.
16
Biogen inc.
74
Biovie inc.
32
Boston scientific corporation
16
Bridgebio pharma, inc.
15
Bristol-myers squibb company
22
Cassava sciences, inc.
26
Centogene n.v.
23
Cognition therapeutics inc
21
Cyclo therapeutics inc - class a
19
Danaher corporation
18
Denali therapeutics inc.
15
Eli lilly and company
89
Gain therapeutics inc
20
Gilead sciences, inc.
20
Glaxosmithkline plc
39
Global blood therapeutics, inc.
33
Horizon therapeutics public limited company
23
Incyte corporation
16
Inmune bio inc.
16
Ionis pharmaceuticals, inc.
14
Jaguar health, inc.
14
Johnson & johnson
107
Koninklijke philips n.v.
15
Medtronic plc
30
Mesoblast limited
24
Novartis ag
76
Novo nordisk a/s
18
Orange
21
Pfizer, inc.
28
Protalix biotherapeutics, inc.
14
Regeneron pharmaceuticals, inc.
16
Regulus therapeutics inc.
23
Sanofi
179
Sutro biopharma, inc.
14
Takeda pharmaceutical company limited
32
Teva pharmaceutical industries ltd
36
Thermo fisher scientific inc
47
Vaxcyte, inc.
14
Vertex pharmaceuticals incorporated
17
Viatris inc.
16
Zyversa therapeutics inc
18
Symbols
ABBV
1
ALNY
3
ALPN
1
AMGN
1
APTX
1
AVXL
1
AZN
2
AZNCF
1
BIIB
1
BIVI
1
BSX
1
CCXI
1
DNLI
1
ENTX
1
FMTX
1
GLAXF
1
GSK
2
INCY
1
IONS
1
JNJ
3
LLY
5
MC
1
MESO
1
NVO
18
NVS
1
NVSEF
1
PFE
1
RETA
1
RVP
1
SLN
1
SLNCF
1
SNY
8
SNYNF
4
VTGN
1
Exchanges
Amex
1
Nasdaq
14
Nyse
18
Crawled Date
2024 - 03 - 25
1
2024 - 03 - 08
1
2024 - 03 - 05
1
2023 - 10 - 09
1
2023 - 09 - 26
1
2023 - 06 - 28
1
2023 - 04 - 19
1
2022 - 09 - 01
1
2022 - 07 - 25
1
2022 - 06 - 27
1
2022 - 05 - 11
1
2021 - 11 - 12
1
2021 - 08 - 06
1
2021 - 07 - 29
1
2021 - 07 - 21
1
2021 - 07 - 09
2
2021 - 06 - 22
1
Crawled Time
02:00
1
04:00
2
10:00
2
12:00
1
12:15
1
12:20
2
13:00
1
14:00
2
15:00
2
15:15
1
19:00
1
21:00
2
Source
www.biospace.com
4
www.globenewswire.com
4
www.prnewswire.com
10
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Disease
entities :
Novo nordisk a::S
save search
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Published:
2024-03-25
(Crawled : 10:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-4.12%
|
O:
0.19%
H:
0.97%
C:
0.04%
disease
pipeline
pharmaceuticals
acquire
cardiovascular
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Published:
2024-03-08
(Crawled : 19:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
Email alert
Add to watchlist
wegovy
obesity
disease
approved
risk
cardiovascular
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Published:
2024-03-05
(Crawled : 10:00)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-3.52%
|
O:
-1.33%
H:
0.46%
C:
-1.27%
disease
kidney
risk
trial
diabetes
flow
The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight
Published:
2023-10-09
(Crawled : 21:00)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
34.1%
|
O:
0.09%
H:
1.41%
C:
0.94%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-8.19%
|
O:
0.67%
H:
0.56%
C:
-0.01%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-15.01%
|
O:
0.51%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-6.1%
|
O:
0.48%
H:
1.39%
C:
0.51%
ALPN
|
$64.465
-0.05%
-0.05%
2.6M
|
Health Technology
|
450.58%
|
O:
-1.07%
H:
0.0%
C:
-6.9%
bleeding
disease
market
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
Published:
2023-09-26
(Crawled : 21:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
-15.3%
|
O:
-0.69%
H:
0.0%
C:
0.0%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
34.49%
|
O:
-0.51%
H:
0.62%
C:
0.42%
BSX
|
$67.96
-0.24%
1.53%
6.2M
|
Health Technology
|
28.94%
|
O:
-0.09%
H:
0.72%
C:
-1.29%
SLN
|
$21.575
1.53%
1.51%
120K
|
Health Technology
|
113.14%
|
O:
-1.3%
H:
2.44%
C:
-1.42%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-15.4%
|
O:
-0.5%
H:
0.0%
C:
0.0%
MESO
|
$5.03
7.25%
6.76%
500K
|
Health Technology
|
-52.34%
|
O:
3.25%
H:
1.57%
C:
-3.15%
IONS
|
$40.93
-1.47%
-1.49%
1.1M
|
Health Technology
|
-10.24%
|
O:
0.99%
H:
2.09%
C:
0.83%
AMGN
|
$264.07
-0.59%
-0.59%
2.2M
|
Health Technology
|
-0.91%
|
O:
1.0%
H:
0.69%
C:
-1.01%
disease
cardiovascular
growth
market
Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast 2023-2032: With Focus on United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan
Published:
2023-06-28
(Crawled : 02:00)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-20.86%
|
O:
1.47%
H:
0.0%
C:
-0.94%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
60.76%
|
O:
0.86%
H:
0.0%
C:
-2.09%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-14.37%
|
O:
0.75%
H:
0.0%
C:
0.0%
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.56%
|
O:
6.1%
H:
5.34%
C:
0.82%
disease
japan
kidney
market
Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight
Published:
2023-04-19
(Crawled : 15:00)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
-27.29%
|
O:
-3.51%
H:
1.28%
C:
0.74%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
101.87%
|
O:
0.17%
H:
0.2%
C:
-0.02%
VTGN
|
$4.69
0.86%
0.85%
110K
|
Health Technology
|
8.62%
|
O:
0.0%
H:
2.59%
C:
-0.49%
DNLI
|
$16.81
-3.06%
-3.15%
1.4M
|
Health Technology
|
-30.97%
|
O:
-1.11%
H:
1.31%
C:
0.56%
BIVI
|
$0.4819
-1.25%
-1.27%
610K
|
Health Technology
|
-94.03%
|
O:
-0.24%
H:
4.29%
C:
0.49%
BIIB
|
$192.13
-1.55%
-1.57%
1.3M
|
Health Technology
|
-33.58%
|
O:
-0.39%
H:
0.4%
C:
-0.14%
APTX
|
$0.061
21.31%
7.8M
|
Health Services
|
-51.97%
|
O:
2.05%
H:
13.81%
C:
11.81%
AVXL
|
$4.065
-1.34%
-1.35%
1.3M
|
Health Technology
|
-49.26%
|
O:
-0.74%
H:
2.73%
C:
1.61%
disease
companies
parkinson's
pipeline
space
trial
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Published:
2022-09-01
(Crawled : 12:20)
- globenewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
16.35%
|
O:
-1.0%
H:
0.41%
C:
-0.49%
MC
|
News
|
$51.26
0.29%
0.0%
310K
|
Finance
|
22.68%
|
O:
-0.62%
H:
0.82%
C:
0.63%
FMTX
|
$20.01
-0.15%
|
Health Technology
|
50.0%
|
O:
48.87%
H:
2.27%
C:
2.07%
blood
rare
acquire
disease
therapeutics
Global Acquired von Willebrand Disease (AvWD) Treatment Market Report 2022-2030 Featuring Key Players - Novo Nordisk A/S, Genentech, Inc., F. Hoffman-La Roche AG, Sanofi SA
Published:
2022-07-25
(Crawled : 14:00)
- prnewswire.com
GLAXF
|
$20.2
-14.18%
510
|
Health Technology
|
-6.05%
|
O:
0.0%
H:
0.0%
C:
0.0%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
7.72%
|
O:
0.83%
H:
0.67%
C:
0.32%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
-5.53%
|
O:
0.76%
H:
0.19%
C:
-1.06%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-7.22%
|
O:
2.0%
H:
0.0%
C:
0.0%
treatment
global
disease
report
roche
acquired
sanofi
market
Valued to be $12.9 Billion by 2026, Crohn`s Disease (CD) Therapy Slated for Robust Growth Worldwide
Published:
2022-06-27
(Crawled : 12:20)
- prnewswire.com
AZNCF
|
$135.305
-4.19%
1.1K
|
Health Technology
|
4.72%
|
O:
-1.55%
H:
4.43%
C:
0.03%
PFE
A
|
$25.42
-1.05%
-0.04%
44M
|
Health Technology
|
-49.37%
|
O:
1.46%
H:
1.45%
C:
0.78%
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
10.41%
|
O:
0.72%
H:
0.0%
C:
0.0%
NVS
|
News
|
$93.08
-0.13%
0.86%
1.2M
|
Health Technology
|
11.12%
|
O:
1.86%
H:
1.05%
C:
0.24%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-19.86%
|
O:
0.78%
H:
0.94%
C:
0.26%
CCXI
|
$51.99
-0.04%
|
Health Technology
|
87.83%
|
O:
-4.88%
H:
1.04%
C:
-1.25%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
2.65%
|
O:
-0.36%
H:
1.22%
C:
0.38%
disease
therapy
growth
Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases
Published:
2022-05-11
(Crawled : 12:00)
- biospace.com/
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
14.9%
|
O:
-2.55%
H:
2.32%
C:
-0.85%
therapeutics
disease
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published:
2021-11-12
(Crawled : 14:00)
- biospace.com/
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
8.67%
|
O:
-0.47%
H:
0.0%
C:
0.0%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
183.9%
|
O:
-0.49%
H:
0.0%
C:
0.0%
ALNY
|
$145.23
-1.02%
-1.03%
500K
|
Health Technology
|
-16.9%
|
O:
-2.06%
H:
0.0%
C:
0.0%
disease
liver disease
phase 1
liver
trial
Global Oral Biologics & Biosimilar Drugs Markets 2021-2030: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis
Published:
2021-08-06
(Crawled : 15:00)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
19.74%
|
O:
-4.5%
H:
0.0%
C:
0.0%
GSK
|
$39.6
-0.88%
0.0%
2.8M
|
Health Technology
|
-2.37%
|
O:
-0.95%
H:
0.23%
C:
-0.3%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-9.28%
|
O:
0.26%
H:
0.0%
C:
0.0%
ENTX
|
$2.14
-6.55%
-7.01%
210K
|
Health Technology
|
-53.64%
|
O:
2.23%
H:
0.0%
C:
-1.39%
AZN
|
$68.53
0.39%
0.39%
3.7M
|
Health Technology
|
16.87%
|
O:
-2.02%
H:
0.09%
C:
-1.38%
RVP
P
|
$1.035
-3.25%
0.48%
180K
|
Health Technology
|
-91.53%
|
O:
-0.08%
H:
1.82%
C:
0.87%
multiple sclerosis
disease
diabetes
drug
sclerosis
psoriasis
biosimilar
Biologics Market Size to Reach USD 477.15 Billion in 2027 | Rapid Advancements in Molecular Therapy and Cell-Based Biologics, Increasing Incidence of Chronic Diseases, are Some Key Factors Driving Industry Growth, says Emergen Research
Published:
2021-07-29
(Crawled : 15:15)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
34.93%
|
O:
0.49%
H:
0.26%
C:
-0.62%
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-16.11%
|
O:
0.33%
H:
0.35%
C:
-0.32%
ABBV
|
$164.25
1.05%
-0.76%
4M
|
Health Technology
|
37.11%
|
O:
0.4%
H:
0.08%
C:
-0.13%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-11.89%
|
O:
-0.69%
H:
0.08%
C:
-0.33%
disease
therapy
molecular
growth
research
merge
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published:
2021-07-21
(Crawled : 13:00)
- biospace.com/
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
41.07%
|
O:
0.9%
H:
0.72%
C:
0.58%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
217.73%
|
O:
0.58%
H:
0.42%
C:
0.38%
ALNY
|
$145.23
-1.02%
-1.03%
500K
|
Health Technology
|
-19.9%
|
O:
0.45%
H:
0.0%
C:
-2.13%
disease
liver disease
treatment
phase 1
results
liver
trial
phase 2
phase 3
Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases
Published:
2021-07-09
(Crawled : 04:00)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
41.73%
|
O:
-1.54%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-10.36%
|
O:
1.0%
H:
0.0%
C:
0.0%
disease
neurodegenerative
Novo Holdings Launches Muna Therapeutics with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases
Published:
2021-07-09
(Crawled : 04:00)
- prnewswire.com
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
41.73%
|
O:
-1.54%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-10.36%
|
O:
1.0%
H:
0.0%
C:
0.0%
disease
neurodegenerative
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published:
2021-06-22
(Crawled : 12:15)
- biospace.com/
NVO
|
News
|
$124.53
0.88%
0.0%
2.6M
|
Health Technology
|
49.36%
|
O:
-0.39%
H:
0.27%
C:
-0.21%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
235.36%
|
O:
-0.02%
H:
0.44%
C:
-0.53%
ALNY
|
$145.23
-1.02%
-1.03%
500K
|
Health Technology
|
-14.33%
|
O:
0.08%
H:
1.01%
C:
0.9%
disease
liver disease
treatment
phase 2
liver
trial
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.